Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes

BackgroundChronic obstructive pulmonary disease (COPD) is increasingly considered a heterogeneous condition. It was hypothesised that COPD, as currently defined, includes different clinically relevant subtypes.MethodsTo identify and validate COPD subtypes, 342 subjects hospitalised for the first tim...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax 2011-05, Vol.66 (5), p.430-437
Hauptverfasser: Garcia-Aymerich, Judith, Gómez, Federico P, Benet, Marta, Farrero, Eva, Basagaña, Xavier, Gayete, Àngel, Paré, Carles, Freixa, Xavier, Ferrer, Jaume, Ferrer, Antoni, Roca, Josep, Gáldiz, Juan B, Sauleda, Jaume, Monsó, Eduard, Gea, Joaquim, Barberà, Joan A, Agustí, Àlvar, Antó, Josep M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundChronic obstructive pulmonary disease (COPD) is increasingly considered a heterogeneous condition. It was hypothesised that COPD, as currently defined, includes different clinically relevant subtypes.MethodsTo identify and validate COPD subtypes, 342 subjects hospitalised for the first time because of a COPD exacerbation were recruited. Three months after discharge, when clinically stable, symptoms and quality of life, lung function, exercise capacity, nutritional status, biomarkers of systemic and bronchial inflammation, sputum microbiology, CT of the thorax and echocardiography were assessed. COPD groups were identified by partitioning cluster analysis and validated prospectively against cause-specific hospitalisations and all-cause mortality during a 4 year follow-up.ResultsThree COPD groups were identified: group 1 (n=126, 67 years) was characterised by severe airflow limitation (postbronchodilator forced expiratory volume in 1 s (FEV1) 38% predicted) and worse performance in most of the respiratory domains of the disease; group 2 (n=125, 69 years) showed milder airflow limitation (FEV1 63% predicted); and group 3 (n=91, 67 years) combined a similarly milder airflow limitation (FEV1 58% predicted) with a high proportion of obesity, cardiovascular disorders, diabetes and systemic inflammation. During follow-up, group 1 had more frequent hospitalisations due to COPD (HR 3.28, p
ISSN:0040-6376
1468-3296
DOI:10.1136/thx.2010.154484